PHETON Holdings Soars 30.34% to 52-Week High Amid Strong IPO and Revenue Surge

Company Overview

PHETON HOLDINGS LTD (NASDAQ: PTHL) is a China-based healthcare technology company specializing in brachytherapy treatment planning systems. Through its wholly owned subsidiary Beijing Feitian Zhaoye Technology Co., Ltd., PHETON develops and commercializes FTTPS, a software platform designed to optimize radioactive particle implantation for cancer therapy.

Corporate Structure

Incorporated in 2022, PHETON operates with a team of ten employees at its Beijing headquarters. The company’s governance structure includes Class A and Class B ordinary shares; as of May 5, 2025, ZJW (BVI) Ltd and Jianfei Zhang collectively held 53.8% of Class A shares on a beneficial basis, with conversion rights that may affect future voting power. On June 16, 2025, investor Ho Thiam Way reported a 5.70% stake in Class A shares under Schedule 13G filings.

Brachytherapy by Amit Gaur

Developments and News

On September 6, 2024, PHETON closed its initial public offering of 2,250,000 Class A ordinary shares at $4.00 each, generating $9 million in gross proceeds. The company granted underwriters a 45-day over-allotment option for 337,500 additional shares. Proceeds were allocated for research and development, technology upgrades, market expansion, and liquidity enhancement.

On June 26, 2025, PTHL shares rose 10.4% in pre-market trading following a quarterly revenue increase of 379.28% year-over-year. Subsequently, as of July 15, 2025, the share price reached $28.05, establishing a 52-week high. Volume at that point reached 4,879,851 shares, significantly above the 10-day average of one million.

Financial and Strategic Analysis

PHETON’s financial profile reflects early-stage commercialization in a specialized medical niche:

• Revenue (TTM): $448,200
• Net loss (TTM): $660,590
• Diluted EPS (TTM): -$0.05
• Price/Sales (TTM): 547.51
• Price/Book (MRQ): 44.45
• Enterprise Value/Revenue: 600.12
• Total cash (MRQ): $6.16 million
• Total debt/equity (MRQ): 4.01%
• Levered free cash flow (TTM): -$1.48 million

Market multiples reflect a challenge in profitability: the trailing net margin is -147.39%, and P/E (TTM) stands at -542.55. The gross margin of 85.04% indicates the high-value nature of software sales. The balance sheet has relatively low leverage and modest cash reserves to support ongoing R&D and operational activities.

Strategically, PHETON’s primary focus is on expanding the adoption of FTTPS in global oncology markets, using IPO proceeds to enhance product features, secure regulatory approvals, and develop sales channels.

Market Position and Industry Context

Within the healthcare technology sector, PHETON addresses a niche in radiotherapeutic treatment planning. Its FTTPS product competes against larger medical-device companies offering broader oncology portfolios. PHETON’s small revenue base and limited operating history position it as a high-growth issuer. Investor interest, reflected in a 444.22% year-to-date share-price increase, indicates engagement with the company’s specialized technology, while also exposing the stock to volatility.

tl;dr

On July 15, 2025, PHETON shares increased by 30.34% to $28.05, reaching a 52-week high before trading was halted, with volume reaching approximately 4.9 million. The company’s IPO on September 6, 2024, raised $9 million for research and development and expansion. As of mid-June 2025, two Schedule 13G filings disclosed significant stakes: ZJW (BVI) Ltd controls 53.8% of Class A shares via conversion rights, and Ho Thiam Way holds 5.70%. Despite a negative net margin and modest revenue of $448,200 (TTM), PHETON maintains strong gross margins and low leverage. Future performance will depend on successful market adoption of its brachytherapy planning system and execution of its product-development roadmap.